**Research Question**: The paper investigates how phagocytosis checkpoints, particularly CD47, influence immune evasion in glioblastoma (GBM), and evaluates emerging therapeutic strategies targeting these mechanisms.

**Methodology:** The authors conducted a comprehensive literature review, examining mechanisms regulating tumor-associated macrophages (TAMs) and phagocytosis in GBM. They explored preclinical and clinical data on immune checkpoint inhibitors, focusing on CD47/SIRPα signaling and other phagocytosis regulators like TREM2, siglecs, and macrophage polarization strategies.

**Key Findings:** CD47 functions as a “don’t eat me” signal, preventing TAM-mediated phagocytosis in GBM. Blocking CD47 with monoclonal antibodies or targeting associated pathways (e.g., LRIG2 or EGFR) enhances macrophage-mediated tumor cell clearance. Other pathways, like TREM2 and sialic acid-binding siglecs, also regulate TAM activity. Innovative approaches, including chimeric antigen receptor macrophages (CAR-Ms), demonstrate potential for boosting phagocytosis and reprogramming the tumor microenvironment.

**Implications:** Targeting phagocytosis checkpoints could synergize with traditional therapies to overcome GBM’s immunosuppressive microenvironment. These strategies may improve the efficacy of current immune checkpoint inhibitors like anti-PD-1/PD-L1 and provide alternative therapeutic options for resistant cases.

**Limitations:** The reviewed approaches face challenges such as systemic toxicity (e.g., CD47 targeting affects non-tumor cells), heterogeneity in GBM tumors and macrophage phenotypes, and limited efficacy in solid tumor models.

**Conclusion:** The study underscores the promise of phagocytosis checkpoint inhibitors and combination therapies for GBM. Further research is needed to optimize delivery mechanisms and minimize off-target effects, paving the way for more effective GBM treatments.